Hey the revenue guidance I am re reading and I think I made a mistake
revenue of 700m seems to me like only existing illuccix sales around the world .
the kidney and brain product sales if approved would start to lead to more revenue and when guidance states will be updated I’m assuming this means in excess to guidance
so essentially 35 to 40 pc in just expected revenue increase from illuccix ? Am I correct in this assumption ?
Ann: Telix 2023 Full Year Results and Investor Webcast/Call, page-28
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$23.34 |
Change
0.350(1.52%) |
Mkt cap ! $7.811B | |||
| Open | High | Low | Value | Volume |
| $23.00 | $23.60 | $23.00 | $22.52M | 965.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2683 | $23.33 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $23.40 | 9186 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |